Anti-Human CD22 Recombinant Antibody (hLL2) (CAT#: TAB-0196CL)

Figure 1 Evaluation of growth-inhibition and apoptosis in D1–1 and Ramos cells.

Cell viabilitydetermined by the MTS assay after 4-day incubation for the Dried-I format of epratuzumab(hLL2*) or labetuzumab (hMN-14*).

Chang, C. H., Wang, Y., Gupta, P., & Goldenberg, D. M. (2015, January). Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. In MAbs (Vol. 7, No. 1, pp. 199-211). Taylor & Francis.

Figure 2 Cytotoxicity of epratuzumab in various formats to Daudi cells.

Epratuzumab pre-sented as the Dried-I (hLL2*) or Wet-III (hLL2 C GAH C anti-IgM) format (right panel), but not theWet-I (hLL2) or Wet-IIB (hLL2 C GAH) format (left panel), induced dose-dependent cytotoxicity inDaudi cells, as measured by the MTS assay.

Chang, C. H., Wang, Y., Gupta, P., & Goldenberg, D. M. (2015, January). Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. In MAbs (Vol. 7, No. 1, pp. 199-211). Taylor & Francis.

Figure 3 Cytotoxicity of epratuzumab in various formats to Daudi cells.

The Dried-I format of epratuzumab (hLL2*)induced apoptosis comparable to the positive control (anti-IgM) as determined by the Annexin Vassay.

Chang, C. H., Wang, Y., Gupta, P., & Goldenberg, D. M. (2015, January). Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. In MAbs (Vol. 7, No. 1, pp. 199-211). Taylor & Francis.

Figure 4 Phosphorylation of CD79a, CD79b, and CD22.

Western blot analyses of phosphorylated CD79a, CD79b,and CD22 in D1–1 cells treated for 2 h with various formats of soluble epratuzumab, including Wet-I(lane 4; hLL2, 7.5 mg/mL), Wet-IIA (lane 5; hLL2, 7.5 mg/mL; GAH, 10 mg/mL), and Wet-III (lane 7; hLL2, 7.5 mg/mL;GAH, 10 mg/mL; anti-IgM, 1 mg/mL). In lane 6, the amounts of GAH and anti-IgM were the same as those in lane 7, but the concentration of epratuzumab was too low (10 ng/mL) to induce a notable effect.

Chang, C. H., Wang, Y., Gupta, P., & Goldenberg, D. M. (2015, January). Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. In MAbs (Vol. 7, No. 1, pp. 199-211). Taylor & Francis.